SC 13G/A: Xilio Therapeutics, Inc.
Ticker: XLO · Form: SC 13G/A · Filed: Nov 14, 2024 · CIK: 1840233
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by Xilio Therapeutics, Inc..
Risk Assessment
Risk Level: low
Filing Stats: 2,769 words · 11 min read · ~9 pages · Grade level 12.2 · Accepted 2024-11-14 17:44:28
Key Financial Figures
- $0.0001 — INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class
Filing Documents
- d909949dsc13ga.htm (SC 13G/A) — 102KB
- d909949dex99a.htm (EX-99.A) — 18KB
- 0001193125-24-258836.txt ( ) — 122KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information in this statement is true, complete and correct. Dated: November 14, 2024 Bain Capital Life Sciences Fund II, L.P. By: Bain Capital Life Sciences Investors II, LLC, its general partner By: Bain Capital Life Sciences Investors, LLC, its manager By: /s/ Andrew Hack Name: Andrew Hack Title: Partner BCLS II Investco, LP By: BCLS II Investco (GP), LLC, its general partner By: Bain Capital Life Sciences Fund II, L.P., its manager By: Bain Capital Life Sciences Investors II, LLC, its general partner By: Bain Capital Life Sciences Investors, LLC, its manager By: /s/ Andrew Hack Name: Andrew Hack Title: Partner BCIP Life Sciences Associates, LP By: Boylston Coinvestors, LLC, its general partner By: /s/ Andrew Hack Name: Andrew Hack Title: Authorized Signatory BCLS II Equity Opportunities, LP By: BCLS II Equity Opportunities GP, LLC, its general partner By: Bain Capital Life Sciences Fund II, L.P., its manager By: Bain Capital Life Sciences Investors II, LLC, its general partner By: Bain Capital Life Sciences Investors, LLC, its manager By: /s/ Andrew Hack Name: Andrew Hack Title: Partner